IN ADULTS AND CHILDREN
Type 2 or 3 SMA (later-onset)
IN INFANTS
Type 1 SMA (infantile-onset)
These are not all of the possible side effects of Evrysdi. For more information on the possible risks and benefits of Evrysdi, speak to your healthcare provider.
No one in the later-onset or infantile-onset clinical studies stopped taking Evrysdi because of side effects after 24 months of treatment
No one in the later-onset or infantile-onset clinical studies stopped taking Evrysdi because of side effects after 24 months of treatment
Safety in people with previously treated SMA (JEWELFISH trial)
Initial safety findings from people who previously took other approved or investigational SMA medications have been consistent with the safety findings from studies in adults, children, and infants who only took Evrysdi.
Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.
Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.